Boman et al. reported that MUC2 were mainly present in benign and borderline ovarian tumor [46], while Dong et al. showed that breast cancer patients with presence of MUC2 expression had shorter disease-free survival [47]. This evidence concerns the gene MUC2 and breast carcinoma.